OROBUPRE (buprenorphine), medicine used in cases of opiate dependence

Moderate clinical benefit in the replacement therapy of addiction to opiates, but no demonstrated clinical advantage over SUBUTEX

• OROBUPRE has been granted a marketing authorisation for the treatment of opiate addiction.

• It is a buprenorphine-based orodispersible tablet administered on the tongue, not sublingually as for SUBUTEX.

• It dissolves more rapidly than SUBUTEX.

• It is not interchangeable with other buprenorphine-containing medicinal products due to its different bioavailability, complicating the implementation of replacement therapy and exposing patients to a risk of overdosage. 

• Its use is not appropriate in patients stabilised with sublingual buprenorphine at doses below 2 mg as lower dosages are not available.